News Column

LIGAND PHARMACEUTICALS INC FILES (8-K) Disclosing Results of Operations and Financial Condition, Financial Statements and Exhibits

July 17, 2014

Item 2.02 Results of Operations and Financial Condition. On July 17, 2014, Ligand Pharmaceuticals Incorporated (the "Company" or "Ligand") issued a press release announcing expected revenue for the quarter ended June 30, 2014. A copy of this press release is furnished herewith as Exhibit 99.1. In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K, including the press release attached hereto as Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 8.01 Other Events. On July 17, 2014, the Company issued a press release announcing that its Board of Directors has authorized the Company to repurchase up to $10.0 million of its common stock from time to time in open-market transactions over the next 12 months.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits. Exhibit No. Description 99.1 Press release of the Company dated July 17, 2014.


For more stories on investments and markets, please see HispanicBusiness' Finance Channel

Source: Edgar Glimpses

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters